Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

IPATASERTIB for Hormone-refractory prostate cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 14 adverse event reports in the FDA FAERS database where IPATASERTIB was used for Hormone-refractory prostate cancer.

Most Reported Side Effects for IPATASERTIB

Side Effect Reports % Deaths Hosp.
Diarrhoea 17 13.6% 4 11
Pyrexia 11 8.8% 0 10
Fatigue 10 8.0% 1 5
Hyperglycaemia 9 7.2% 3 5
Rash 8 6.4% 2 4
Nausea 7 5.6% 2 2
Vomiting 7 5.6% 2 3
Acute kidney injury 6 4.8% 0 6
Pneumonitis 6 4.8% 1 2
Rash maculo-papular 6 4.8% 0 4
Anaemia 5 4.0% 2 2
Dehydration 5 4.0% 0 5
Drug ineffective 5 4.0% 0 1

Other Indications for IPATASERTIB

Triple negative breast cancer (26) Breast cancer (17) Prostate cancer (11) Breast cancer metastatic (9) Prostate cancer metastatic (8) Her2 negative breast cancer (7) Neoplasm (7)

Other Drugs Used for Hormone-refractory prostate cancer

ENZALUTAMIDE (8,881) RADIUM RA-223 DICHLORIDE (1,615) ABIRATERONE (1,378) DOCETAXEL (674) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (579) DAROLUTAMIDE (553) CABAZITAXEL (524) PREDNISONE (474) APALUTAMIDE (365) OLAPARIB (313)

Related Pages

IPATASERTIB Full Profile All Hormone-refractory prostate cancer Drugs IPATASERTIB Demographics IPATASERTIB Timeline